Equity · Healthcare
OMCL
NASDAQOmnicell (OMCL)
This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.
- Market cap
- 2.1B USD
- P/E (TTM)
- 47.8
- Revenue, year to Dec 2025
- 1.2B USD
- EPS, diluted, year to Dec 2025
- 0.04 USD
- 52-week range
- 26.87 USD – 51.40 USD
- Avg volume
- 156.9K
as of Jul 17, 2026
Have Omnicell (OMCL) insiders bought or sold shares recently?
In the 90 days to 10 Nov 2026, Omnicell insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 15 Nov 2025, show no open-market purchase.
Form 4, 90 days to 10 Nov 2026, newest reported trade 17 Aug 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 17 Aug 2026 | Njoku NnamdiPresident & COO | Sell | 3,083 | 114K USD |
4 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 15 Aug 2026 | LIPPS RANDALL ACHAIRMAN, CEO | Tax withheld | 12,350 | 461K USD |
| 15 Aug 2026 | Manley Corey JEVP&CHIEF LEGAL/ADMIN OFFICER | Tax withheld | 4,025 | 150K USD |
| 15 Aug 2026 | NUTT BRIAN H.VP, Chief Accounting Officer | Tax withheld | 937 | 35K USD |
| 15 Aug 2026 | Njoku NnamdiPresident & COO | Tax withheld | 3,670 | 137K USD |
Which funds hold Omnicell (OMCL)?
10 of the 45 institutional funds we track reported a Omnicell position for the quarter ended 30 Jun 2026 — a combined 163.5M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Millennium Management | Held (±25%) | 1,734,375 | 72.0M USD | −24.2% |
| Two Sigma Investments | Held (±25%) | 794,781 | 33.0M USD | −24.4% |
| Renaissance Technologies | Held (±25%) | 596,243 | 24.8M USD | +23.4% |
| D. E. Shaw & Co. | Trimmed | 287,461 | 11.9M USD | −46.2% |
| Citadel Advisors | New position | 205,406 | 8.5M USD | |
| Point72 Asset Management | Held (±25%) | 143,206 | 5.9M USD | −23.0% |
| Man Group | Added | 76,339 | 3.2M USD | +178.2% |
| Bridgewater Associates | New position | 57,714 | 2.4M USD | |
| AQR Capital Management | Held (±25%) | 36,561 | 1.5M USD | +14.8% |
| Balyasny Asset Management | Held (±25%) | 5,175 | 215K USD | −19.6% |
Have members of Congress traded Omnicell (OMCL)?
The most recent congressional trade disclosed in Omnicell is a sale by Sara Jacobs (house, CA), dated 09 Apr 2021.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 09 Apr 2021 | Sara Jacobshouse · Democrat–CA | Sale | 50K USD–100K USD | 49 days |
What has been filed or recorded for Omnicell (OMCL)?
The filings we hold for Omnicell, newest first: 2 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 09 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 27 shares | 940 USD notional · <0.001% of shares out |
| 01 Oct 2026 | Fails to deliver | Shares failed to deliver | 31 shares | 1K USD notional · <0.001% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS 0.24 USD | |
| 30 Sep 2026 | Financials | Total assets | 2.1B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 1.3B USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS 0.52 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS 0.25 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS 0.04 USD | |
| 31 Dec 2025 | Financials | Revenue | 1.2B USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | 2.1M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | 0.04 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS 0.12 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS 0.12 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.15 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS 0.27 USD |
What do people ask about Omnicell (OMCL)?
What is Omnicell’s market cap?2.1B
Omnicell is worth 2.1B USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.
What is Omnicell’s P/E ratio?47.8
Omnicell has a price-to-earnings ratio of 47.8, as of 17 Jul 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.
What is Omnicell’s revenue?1.2B
Omnicell reported revenue of 1.2B USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Omnicell insiders bought or sold shares recently?1 sale
In the 90 days to 10 Nov 2026, Omnicell insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 15 Nov 2025, show no open-market purchase. A further 4 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Omnicell?10 of 45
10 of the 45 funds we track reported a Omnicell position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Millennium Management, Two Sigma Investments and Renaissance Technologies. See Funds
Have members of Congress traded Omnicell?1 trade
Yes. 1 trade in Omnicell appears in the congressional disclosures we hold: a sale by Sara Jacobs (House, CA) dated 9 Apr 2021, filed 28 May 2021. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Omnicell last report earnings?0.24
Omnicell last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of 0.24 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close)
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- Wikimedia CommonsPortraits via Wikimedia Commons. Sara Jacobs: Kristie Baxter, Public domain.
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings